Cigna to invest $250M through new venture capital fund

Healthcare services company Cigna has launched a $250 million venture capital fund, Cigna Ventures. The fund will focus on transformative and innovative healthcare companies, including promising startups and growth-stage companies, according to the announcement.

Specifically, the fund will look at three strategic areas: insights and analytics, digital health and retail, and care delivery and management.

“Cigna’s commitment to improving the health, well-being and sense of security of the people we serve is at the front and center of everything we do,” Tom Richards, senior vice president and global lead, strategy and business development at Cigna, said in a statement. “The venture fund will enable us to drive innovation beyond our existing core business operations, and incubate new ideas, opportunities and relationships that have the potential for long-term business growth and to help our customers.”

Cigna is already involved in venture activity, with an equal number of both direct investments and a collaboration with five venture capital partners. Cigna has led the C1 round of financing for Omada Health, as well as made investments in Prognos, Contessa Health, MDLIVE, and Cricket Health.

Cigna is not the only company ramping up its investments in healthcare startups. Google parent company Alphabet recently benchmarked an additional $375 million in healthcare insurance startup Oscar Health. Late last year, UnitedHealth’s Optum launched its own $250 million venture capital fund focused on data analytics and digital health, Optum Ventures.

Cigna did not respond to media requests from HealthExec as of Wednesday afternoon.

The healthcare services company is also in the midst of acquiring pharmacy benefits manager Express Scripts for $67 billion

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.